After a soft start to the year, the IPO market has witnessed muted activity so far though a few big companies entered
Prime Medicine is the next big biotech to pursue IPO. Here’s all you need to know
Categories
Biotech
Biogen posts Q3 earnings well above estimates
Biogen (NASDAQ: BIIB) reported third-quarter 2021 financial results before the regular market hours on Wednesday. The company reported Q3 revenue of $2.78
Gilead Sciences, Inc (GILD): Q3 2019 Earnings Snapshot
-- Gilead Sciences (NYSE: GILD) reported third-quarter 2019 earnings of $1.75 per share, vs. $1.74 per share expected. -- Total revenue remained
Alexion Pharmaceuticals, (ALXN): Q3 2019 Earnings Snapshot
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported third-quarter 2019 earnings of $2.79 per share, vs. $2.47 per share expected. Revenues grew 23% to
Thermo Fisher Scientific (TMO): Q3 2019 Earnings Snapshot
-- Thermo Fisher Scientific (NYSE: TMO) reported third-quarter 2019 earnings of $2.94 per share, vs. $2.87 per share expected. -- Revenues grew
Biogen (BIIB) Q3 profit rises 7% on spinal muscular atrophy drug addition
Biogen Inc. (NASDAQ: BIIB) reported a 7% increase in earnings for the third quarter of 2019 as spinal muscular atrophy drug Spinraza
4 biotech stocks that are ideal takeover targets
Speculation plays a big role when investing in biotech stocks, hence making them highly volatile. It could be after years of stock
Bio-Path’s loss expands in Q2
Biotech company Bio-Path Holdings (NASDAQ: BPTH) reported a loss of $2.5 million or $0.87 per share for the second quarter ended June
Earnings preview: Will losses continue for Celsion in Q2
Celsion Corporation (NASDAQ: CLSN) is set to release its earnings results for the second quarter on Thursday before the market opens. The
Progenics posts wider-than-expected loss in Q2
Progenics Pharmaceuticals (NASDAQ: PGNX) reported a wider loss in the second quarter due to higher costs and expenses despite a jump in
What to look for when Progenics Pharma posts Q2 earnings
Progenics Pharmaceuticals (NASDAQ: PGNX) is set to release its earnings results for the second quarter of 2019 on Friday before the market
Is Advaxis exhausting its financial resources with the stock hitting a record low?
Advaxis Inc. (NASDAQ: ADXS) stock plunged to a record low of $1.54 on Tuesday as the late-stage biotech company has returned the
Cara Therapeutics Q1 loss widens but beats estimates
Cara Therapeutics Inc. (NASDAQ: CARA) reported a wider loss in the first quarter of 2019 due to higher costs and expenses. The bottom
ImmunoGen is cheap ahead of Q1 earnings, but is it worth?
ImmunoGen Inc (NASDAQ: IMGN) is one of the worst performing stocks out there, losing about 78% of its value over the course
Biocept narrows loss in Q4
Biocept (BIOC) narrowed its loss in the fourth quarter, beating analyst estimates. However, sales failed to impress the street. Shares of the
Earnings preview: What’s on the cards for Biocept in Q4
Biocept (BIOC) is scheduled to report fourth quarter and full year 2018 results on March 28, Thursday, after the regular trading hours.
Earnings: Affimed cuts down losses in 2018
Affimed N.V. (AFMD), a clinical stage biopharmaceutical company that focuses on oncology drugs, Wednesday reported net losses that narrowed in 2018, helped
Onconova Therapeutics cuts down losses in 2018
Onconova Therapeutics (ONTX), a Phase 3 biopharmaceutical company that focuses on developing cancer drugs, Tuesday posted a narrowed loss in fiscal 2018
Earnings Preview: Aeterna Zentaris reporting Q4 results on Mar 26
Aeterna Zentaris (AEZS) is scheduled to report its fourth-quarter financial results on March 26, Tuesday, after the regular trading hours. The specialty
What is NASH and which biotech firms are vying for the first-mover status
NASH, or Nonalcoholic steatohepatitis, is undeniably a golden goose in the pharma space. The biggest corporate attraction towards this liver disorder is
Earnings: Trevena slips on wider-than-expected Q4 loss
Trevena Inc (TRVN) Wednesday reported fourth-quarter losses that were wider than analysts’ estimates, sending its shares down 5.4% during pre-market trading. Helped